PETA Urges Review of Pfizer Drug Testing Practices Over Primate Health Concerns

Key Facts

PETA has called for a formal review of Pfizer's drug testing practices following the disclosure of records suggesting the use of unhealthy primates in clinical research. The organization alleges that the pharmaceutical giant utilized monkeys with pre-existing health conditions at the New Iberia Research Center (NIRC) without disqualifying them from human health studies. According to the allegations, the use of sick animals could lead to inaccurate results for human health applications, potentially compromising scientific data integrity. The case also involves Charles River Laboratories as a partner in these controversial testing procedures. Analysts suggest that these developments pose reputational and ESG risks for the companies involved. While these allegations currently stem from an activist group rather than government enforcement, they may lead to increased regulatory scrutiny across the pharmaceutical sector.